Abstract:
The present invention discloses a capsule endoscope and a method to prevent the capsule from being covered by a residue or mucous in a patient's digestive tract. The capsule endoscope comprises an improved surface, preventing a residue or mucous to adhere onto the surface of the capsule, and in the unlikely event that a residue or a mucous is collected by the capsule the improved surface can allow an easy and successful clean before an image is taken.
Abstract:
The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.
Abstract:
Compounds of formula I may be used in optoelectronic devices wherein R1 is, independently at each occurrence, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; a is, independently at each occurrence, an integer ranging from 0-4; b is 0, 1 or 2; Ar1 is a direct bond or heteroaryl, aryl, or alkyl or cycloalkyl; Ar2 is heteroaryl, aryl, or alkyl or cycloalkyl; c is an integer ranging from 1-7; and n is an integer ranging from 2-4.
Abstract:
An inkjet printing correction method is used with an inkjet printing apparatus. The inkjet printing correction method includes the following steps. Firstly, a first test image file is printed out as a print test pattern by the inkjet printing apparatus. Then, the print test pattern is scanned to obtain a second test image file. Then, all second block intervals are compared with respective first block intervals, thereby obtaining correction interval difference data. According to the comparing results, a procedure of ejecting ink droplets from the ink nozzles is determined to be advanced or delayed.
Abstract:
The present invention relates to compounds useful as Chemokine Receptor antagonists. Compounds of general formula I are provided: or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compounds and compositions for the inhibition of Chemokine Receptors and also for the treatment of various diseases, conditions, or disorders, including acute or chronic inflammatory disease, cancer or osteolytic bone disorders.
Abstract:
Compounds of formula I may be used in optoelectronic devices wherein R1, R2 and R4 are, independently at each occurrence, H, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; R3 is H or a is, independently at each occurrence, 1 or 2; b is, independently at each occurrence, an integer ranging from 0-3; c is, independently at each occurrence, an integer ranging from 0-4; Ar is independently at each occurrence, H, or heteroaryl; and at least two of Ar are heteroaryl.
Abstract:
Compositions comprising at least one phosphorescent organometallic compound and a polymer comprising structural units of formula II are useful in organic light emitting devices wherein R1, R2, and R4 are independently at each occurrence a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; wherein R3 and R5 are independently selected from the group consisting of hydrogen, triphenylsilyl, t-butyl, mesityl, diphenyl phosphine oxide, and diphenyl phosphine sulfide; and a, b and d are independently 0 or an integer ranging from 1 to 3.
Abstract:
The invention relates to a polymer comprising structural unit of formula II: wherein R1, R2, R3, R4, R5, R6 and R7 are independently at each occurrence a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; a, b, d, e and f are independently at each occurrence 0, or an integer ranging from 1 to 4; c and g are independently at each occurrence 0, or an integer ranging from 1 to 3. In another aspect, the invention relates to monomers for preparing the polymers. In yet another aspect, the invention relates to an optical electronic device comprising a polymer comprising structural unit of formula II.
Abstract:
An optoelectronic device comprises a cathode; an electron-transporting layer comprising a compound of formula I; a light emitting-layer; and an anode; wherein R1 and R2 are independently at each occurrence, hydrogen, a C1-C20 aliphatic radical, a C3-C20 aromatic radical, or a C3-C20 cycloaliphatic radical; R3 is H or alkyl; a and b are, independently at each occurrence 0, or an integer ranging from 1 to 3; n is 2 or 3; and Ar is an aryl.
Abstract:
The present invention provides compositions comprising at least one novel polymeric organic iridium compound which comprises at least one cyclometallated ligand and at least one ketopyrrole ligand. The polymeric organic iridium compositions of the present invention are referred to as Type (2) organic iridium compositions and are constituted such that at least one ligand of the novel organic iridium compound has a number average molecular weight of 2,000 grams per mole or greater (as measured by gel permeation chromatography). Type (2) organic iridium compositions are referred to herein as comprising “polymeric organic iridium complexes”. The novel organic iridium compositions are useful in optoelectronic electronic devices such as OLED devices and photovoltaic devices. In one aspect, the invention provides novel organic iridium compositions useful in the preparation of OLED devices exhibiting enhanced color properties and light output efficiencies.